Show simple item record

dc.contributor.authorWang, Limin
dc.contributor.authorWeiss, Mark L.
dc.contributor.authorDetamore, Michael S.
dc.date.accessioned2016-02-12T21:39:31Z
dc.date.available2016-02-12T21:39:31Z
dc.date.issued2013
dc.identifier.citationWang, Limin, Mark Weiss, and Michael Detamore. "Recent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton’s Jelly Cells." Recent Patents on Regenerative Medicine RPGM 3.3 (2013): 182-92. doi:10.2174/22102965113039990020.en_US
dc.identifier.urihttp://hdl.handle.net/1808/20052
dc.descriptionThis is the author's accepted manuscript. Made available by the permission of the publisher.en_US
dc.description.abstractUmbilical cord mesenchymal stromal cells (UCMSCs) are isolated from Wharton's jelly in the umbilical cord at birth, and offer advantages over adult mesenchymal stromal cells (MSCs) such as highly efficient isolation, faster proliferation in vitro, a broader differentiation potential, and non-invasive harvesting procedure. Their expansion and differentiation potential renders them a promising cell source for tissue engineering and clinical applications. This review discusses recent updates on the differentiation strategies for musculoskeletal tissue engineering including cartilage, bone, and muscle. In addition to tissue engineering applications, UCMSCs can be utilized to support hematopoiesis and modulate immune response. We review the patents relevant to the application of MSCs including UCMSCs in hematopoiesis and immune modulation. Finally, the current hurdles in the clinical translation of UCMSCs are discussed. During clinical translation, it is critical to develop large-scale manufacturing of UCMSCs as well as the composition of expansion and differentiation media. Four clinical trials to date have examined the safety and efficacy of UCMSCs. Once public banking of UCMSCs is available to supply matched allogeneic units and once UCMSC manufacturing is standardized, we anticipate that UCMSCs will be more widely used in clinical trials.en_US
dc.publisherBentham Science Publishersen_US
dc.subjectClinical studyen_US
dc.subjectCommercializationen_US
dc.subjectImmune modulationen_US
dc.subjectMesenchymal stromal cellen_US
dc.subjectUmbilical corden_US
dc.subjectWharton's jellyen_US
dc.titleRecent Patents Pertaining to Immune Modulation and Musculoskeletal Regeneration with Wharton's Jelly Cellsen_US
dc.typeArticle
kusw.kuauthorDetamore, Michael S.
kusw.kudepartmentPharmaceutical Chemistryen_US
dc.identifier.doi10.2174/22102965113039990020
kusw.oaversionScholarly/refereed, author accepted manuscript
kusw.oapolicyThis item meets KU Open Access policy criteria.
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record